PTC Therapeutics (NASDAQ:PTCT)‘s stock had its “buy” rating reiterated by stock analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They presently have a $84.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $100.00. JPMorgan Chase & Co.’s […]
